H. Lundbeck A/S

Copenhagen Stock Exchange HLUN-B.CO

H. Lundbeck A/S Return on Equity (ROE) for the year ending December 31, 2023: 10.39%

H. Lundbeck A/S Return on Equity (ROE) is 10.39% for the year ending December 31, 2023, a 12.66% change year over year. Return on equity measures profit against shareholder equity; higher ROE indicates superior profitability and value creation.

H. Lundbeck A/S Return on Equity (ROE) for the year ending December 31, 2022 was 9.22%, a 27.88% change year over year.
H. Lundbeck A/S Return on Equity (ROE) for the year ending December 31, 2021 was 7.21%, a -22.59% change year over year.
H. Lundbeck A/S Return on Equity (ROE) for the year ending December 31, 2020 was 9.31%, a -49.17% change year over year.
H. Lundbeck A/S Return on Equity (ROE) for the year ending December 31, 2019 was 18.32%, a -33.16% change year over year.

Key data

Date	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio

Copenhagen Stock Exchange: HLUN-B.CO

H. Lundbeck A/S

CEO	Mr. Charl van Zyl
IPO Date	June 10, 2022
Location	Denmark
Headquarters	Ottiliavej 9
Employees	5,800
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership collaboration with Otsuka Pharmaceuticals Co., Ltd.; and collaboration with FeetMe focusing on the use of sensor shoe soles. H. Lundbeck A/S also has a collaboration with Alloy Therapeutics, Inc. for the discovery of novel biologics therapies. The company was founded in 1915 and is headquartered in Valby, Denmark.

Key trends

Past 5 years